Form 4: Revolution Medicines Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Anthony Mancini, See Remarks of Revolution Medicines, Inc., sold 15,448 shares of common stock on September 10, 2026.

Summary

  • Option exercise/conversion: acquired 9,363 Common Stock at $33.62 ($314,784) on September 10, 2026; holds 59,338 after (Direct).
  • Open-market sale: disposed of 6,019 Common Stock at $203.28 ($1,223,569) on September 10, 2026; holds 53,319 after (Direct).
  • Open-market sale: disposed of 5,530 Common Stock at $204.14 ($1,128,870) on September 10, 2026; holds 47,789 after (Direct).
  • Open-market sale: disposed of 2,420 Common Stock at $205.05 ($496,224) on September 10, 2026; holds 45,369 after (Direct).
  • Open-market sale: disposed of 1,179 Common Stock at $206.10 ($242,991) on September 10, 2026; holds 44,190 after (Direct).
  • Open-market sale: disposed of 300 Common Stock at $207.17 ($62,152) on September 10, 2026; holds 43,890 after (Direct).
  • Option exercise/conversion: disposed of 9,363 Stock Option (Right to Buy) on September 10, 2026; holds 96,746 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $3,153,807 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Anthony Mancini — Officer (See Remarks)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-09-10Option exercise/conversionCommon Stock9,363$34$314.8K59,338
2026-09-10Open-market saleCommon Stock6,019$203$1.2M53,319
2026-09-10Open-market saleCommon Stock5,530$204$1.1M47,789
2026-09-10Open-market saleCommon Stock2,420$205$496.2K45,369
2026-09-10Open-market saleCommon Stock1,179$206$243.0K44,190
2026-09-10Open-market saleCommon Stock300$207$62.2K43,890
2026-09-10Option exercise/conversionStock Option (Right to Buy)9,363——96,746

Key Dates

DateDescription
2026-09-10Option exercise/conversion (9,363 shares)
2026-09-10Open-market sale (6,019 shares)
2026-09-10Open-market sale (5,530 shares)
2026-09-10Open-market sale (2,420 shares)
2026-09-10Open-market sale (1,179 shares)
2026-09-10Open-market sale (300 shares)
2026-09-10Option exercise/conversion (9,363 shares)

Keywords

insider transaction, Form 4, RVMD, Revolution Medicines, Inc., bearish, Anthony Mancini

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.